Want to join the conversation?
$REGN, which competes with $AMGN & Novartis AG, said that 4Q15 EYLEA US net sales grew 44% YoverY to $746MM. The market share of treated eyes for EYLEA and DME is roughly double that of ranibizumab and similar to that for off-label bevacizumab. Praluent net sales were $7MM, which understates actual physician and patient demand.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.